» Articles » PMID: 33567105

The Association of Prediagnostic Circulating Levels of Cardiometabolic Markers, Testosterone and Sex Hormone-binding Globulin with Risk of Breast Cancer Among Normal Weight Postmenopausal Women in the UK Biobank

Overview
Journal Int J Cancer
Specialty Oncology
Date 2021 Feb 10
PMID 33567105
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Emerging evidence suggests that normal weight postmenopausal women with a relative excess of body fat are at increased breast cancer risk. However, little is known about the associations between obesity-related blood markers and risk of breast cancer among these individuals. In this prospective study comprising 58 629 normal weight postmenopausal women (body mass index between 18.5 kg/m and 24.9 kg/m ) who were enrolled in the UK Biobank cohort between 2006 and 2010, we examined the associations of glycated hemoglobin, triglycerides, high-density lipoprotein cholesterol, C-reactive protein (CRP), testosterone and sex hormone-binding globulin (SHBG) with risk of breast cancer. A total of 1268 postmenopausal breast cancer cases were ascertained during a median follow-up period of 7 years. Women with CRP, total testosterone and free testosterone (FT) levels in the highest quintile had increased risk of breast cancer compared to those in the lowest quintile (HR : 1.35, 95% confidence interval [CI]: 1.12-1.63, HR : 1.47, 95% CI: 1.20-1.80 and HR : 1.53, 95% CI: 1.23-1.90, respectively), whereas those with SHBG in the highest quintile had reduced risk (HR : 0.70, 95% CI: 0.56-0.88). These associations were attenuated but persisted after additional adjustment for BMI, fat mass index (whole body fat mass [kg]/height [m ]) or waist circumference and after mutual adjustment for testosterone, CRP and/or SHBG. Our study suggests that the risk of postmenopausal breast cancer among normal weight women is increased in association with relatively high levels of CRP and testosterone and with relatively low levels of SHBG.

Citing Articles

Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review.

Leone A, Bonadonna S, Cassani C, Barcellini A, Sirico M, Tagliaferri B BMJ Oncol. 2025; 3(1):e000330.

PMID: 39886120 PMC: 11235029. DOI: 10.1136/bmjonc-2024-000330.


Efficacy of Concurrent Training in Breast Cancer Survivors: A Systematic Review and Meta-Analysis of Physical, Psychological, and Biomarker Variables.

Madeira R, Esteves D, Maia A, Alves A, Marques D, Neiva H Healthcare (Basel). 2025; 13(1.

PMID: 39791640 PMC: 11719466. DOI: 10.3390/healthcare13010033.


Associations of tubal ligation and hysterectomy with serum androgen and estrogen metabolites among postmenopausal women in the Women's Health Initiative Observational Study.

Geczik A, Michels K, Anderson G, Falk R, Farland L, Manson J Cancer Causes Control. 2024; 35(9):1283-1295.

PMID: 38772931 PMC: 11441446. DOI: 10.1007/s10552-024-01882-4.


Remnant cholesterol is an effective biomarker for predicting survival in patients with breast cancer.

Shi J, Liu T, Liu C, Zhang H, Ruan G, Xie H Nutr J. 2024; 23(1):45.

PMID: 38644466 PMC: 11034071. DOI: 10.1186/s12937-024-00951-3.


Multi-Trait Body Shape Phenotypes and Breast Cancer Risk in Postmenopausal Women: A Causal Mediation Analysis in the UK Biobank Cohort.

Amadou A, Freisling H, Sedlmeier A, Bohmann P, Fontvieille E, Weber A J Epidemiol Glob Health. 2024; 14(2):420-432.

PMID: 38598163 PMC: 11176278. DOI: 10.1007/s44197-024-00226-4.